Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company advancing azenosertib, an investigational first-in-class oral inhibitor of the WEE1 kinase for the treatment of ovarian cancer and other solid tumors. It pursues a biomarker-directed strategy to develop a targeted, non-chemotherapy oral therapy option.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -26.9 | — |
| Q3 2025 | 0 | — | -26.7 | — |
| Q4 2025 | 0 | — | -35.2 | — |
| Q1 2026 | 0 | — | -35.4 | — |
| Q2 2026 | 0 | — | -42.3 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Chicago Atlantic BDC, Inc. (LIEN), ZenaTech, Inc. (ZENA), MacroGenics, Inc. (MGNX), Jones Ventures INTL Acquisition1 Corp (JONE), HMH Holding Inc. (HMH), Larimar Therapeutics, Inc. (LRMR)